301 related articles for article (PubMed ID: 28637789)
1. Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity.
Saly DL; Perazella MA
Am J Physiol Renal Physiol; 2017 Oct; 313(4):F951-F954. PubMed ID: 28637789
[TBL] [Abstract][Full Text] [Related]
2. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
[TBL] [Abstract][Full Text] [Related]
3. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.
Perlman A; Heyman SN; Matok I; Stokar J; Muszkat M; Szalat A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1108-1113. PubMed ID: 29174031
[TBL] [Abstract][Full Text] [Related]
4. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
Raskin P
Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
[TBL] [Abstract][Full Text] [Related]
6. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
Chrysant SG
Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
[TBL] [Abstract][Full Text] [Related]
7. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
[TBL] [Abstract][Full Text] [Related]
8. Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury?
Copur S; Yildiz A; Basile C; Tuttle KR; Kanbay M
J Nephrol; 2023 Jan; 36(1):31-43. PubMed ID: 35962863
[TBL] [Abstract][Full Text] [Related]
9. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials.
Gilbert RE; Thorpe KE
Diabetes Obes Metab; 2019 Aug; 21(8):1996-2000. PubMed ID: 31050116
[TBL] [Abstract][Full Text] [Related]
10. Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.
Nadkarni GN; Ferrandino R; Chang A; Surapaneni A; Chauhan K; Poojary P; Saha A; Ferket B; Grams ME; Coca SG
Diabetes Care; 2017 Nov; 40(11):1479-1485. PubMed ID: 28827404
[TBL] [Abstract][Full Text] [Related]
11. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.
Qiu H; Novikov A; Vallon V
Diabetes Metab Res Rev; 2017 Jul; 33(5):. PubMed ID: 28099783
[TBL] [Abstract][Full Text] [Related]
12. Clinical Spectrum and Mechanism of Acute Kidney Injury in Patients with Diabetes Mellitus on SGLT-2 Inhibitors.
Perlman A; Heyman SN; Stokar J; Darmon D; Muszkat M; Szalat A
Isr Med Assoc J; 2018 Aug; 20(8):513-516. PubMed ID: 30084579
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibition and kidney protection.
Nespoux J; Vallon V
Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
[TBL] [Abstract][Full Text] [Related]
14. [Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors in CKD].
Insalaco M; Zanoli L; Rastelli S; Lentini P; Rapisarda F; Fatuzzo P; Castellino P; Granata A
G Ital Nefrol; 2015; 32(4):. PubMed ID: 26252258
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
Jabbour SA
Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
[TBL] [Abstract][Full Text] [Related]
16. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Baker ML; Perazella MA
J Nephrol; 2020 Oct; 33(5):985-994. PubMed ID: 32067179
[TBL] [Abstract][Full Text] [Related]
18. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.
Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei
Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.
Ghosh RK; Ghosh SM; Chawla S; Jasdanwala SA
J Clin Pharmacol; 2012 Apr; 52(4):457-63. PubMed ID: 21543663
[TBL] [Abstract][Full Text] [Related]
20. EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT.
Tahir H; Wani A; Daruwalla V; Daboul N; Sagi J
J Ayub Med Coll Abbottabad; 2015; 27(4):923-4. PubMed ID: 27004352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]